TriangleNCT02301364 · OUTCOME
Overall Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- days
- Interval / dispersion
- Full Range
- Time frame
- 2 years
What was measured
Overall survival time is defined as the time from treatment start to the date of death due to any cause.
Groups in this outcome
Buparlisib (BKM120)
This is an open-label, phase II trial of the pan-PI3K inhibitor buparlisib (BKM120) for patients with recurrent or refractory primary central nervous lymphoma (PCNSL) and recurrent or refractory secondary central nervous lymphoma (SCNSL).
| Group | Source count |
|---|---|
| Buparlisib (BKM120) | 4 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Buparlisib (BKM120) | 196 | Not reported | 54 | 284 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 54
- upper Limit
- 284
- value
- 196
- denoms
- counts
- group Id
- OG000
- value
- 4
- units
- Participants
- description
- Overall survival time is defined as the time from treatment start to the date of death due to any cause.
- dispersion Type
- Full Range
- groups
- description
- This is an open-label, phase II trial of the pan-PI3K inhibitor buparlisib (BKM120) for patients with recurrent or refractory primary central nervous lymphoma (PCNSL) and recurrent or refractory secondary central nervous lymphoma (SCNSL).
- id
- OG000
- title
- Buparlisib (BKM120)
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- 2 years
- title
- Overall Survival
- type
- SECONDARY
- unit Of Measure
- days
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice